Completed PHASE2/PHASE3 NCT00814242

Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels

A Randomized Control Trial of Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels

Sponsor: Eastern Hepatobiliary Surgery Hospital

Conditions Hepatocellular Carcinoma

Interventions percutaneous radiationfrequency ablation surgical resection

Updated 5 times since 2017 Last updated: Mar 30, 2016 Started: Dec 31, 2008 Primary completion: Dec 31, 2009 Completion: Nov 30, 2011

This PHASE2/PHASE3 trial investigates Hepatocellular Carcinoma and is currently completed. Eastern Hepatobiliary Surgery Hospital leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Dec 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eastern Hepatobiliary Surgery Hospital

Data source: Eastern Hepatobiliary Surgery Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China